Successful and rapid clearance of severe, treatment‐resistant atopic dermatitis with dupilumab in a 3‐year‐old

Abstract

Dupilumab is a monoclonal antibody which selectively inhibits the α-subunit of IL-4 and IL-13, which are involved in the pathogenesis of atopic dermatitis. It is the only targeted systemic treatment FDA approved to treat moderate-to-severe atopic dermatitis in adolescents and adults. 1 As systemic treatment for severe atopic dermatitis in children under 6 years of age is lacking, off-label use of dupilumab is

Successful Treatment of Erythrodermic Atopic Dermatitis with Dupilumab in a 5-Year-Old Girl

“…Another case of an off-label successful use of dupilumab has been described in a three-year-old Caucasian girl with loading dose of 200 mg, followed by 100 mg every 2 weeks leading to a clinical resolution within 4 weeks of therapy. [ 3 ] A Phase 2 trial to evaluate effectiveness and safety after single dose of dupilumab therapy in children aged six months to six years has shown a good safety profile as well as efficacy. [ 4 ] Large scale Phase 3 trials are currently underway.…”